More on ABBV
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $259.99 |
|
|||
| Open | $262.70 | ||||
| 52 Wk High | $68.12 | ||||
| 52 Wk Low | $50.71 | ||||
| Day High | $262.97 | ||||
| Day Low | $257.70 | ||||
| P/E | 56.77 | ||||
| EPS | $4.61 | ||||
| Volume | 4,225,417 | ||||
- Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
- SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
- AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference
- AbbVie seeks EMA approval for Skyrizi subcutaneous use in Crohn's
- AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
- AbbVie lung cancer drug data shows high response rates at WCLC 2026
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- Abbvie (ABBV) PT Raised to $303 at Piper Sandler
- Form 4 AbbVie Inc. For: Aug 14 Filed by: Donoghoe Nicholas
- Form 8-K AbbVie Inc. For: Aug 18
Entities mentioned with ABBV
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Dividend | View Related Stories »
- Show More...
